Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders
Jennifer La, Julie Wu, Westyn Branch‐Elliman, et al.
Blood (2022) Vol. 140, Iss. 7, pp. 782-785
Open Access | Times Cited: 11

Showing 11 citing articles:

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Severe COVID-19 in Vaccinated Adults With Hematologic Cancers in the Veterans Health Administration
Sonia T. Anand, Austin D. Vo, Jennifer La, et al.
JAMA Network Open (2024) Vol. 7, Iss. 2, pp. e240288-e240288
Open Access | Times Cited: 9
A Machine Learning approach to identify groups of patients with hematological malignant disorders
Pablo Rodríguez-Belenguer, José Luís Piñana, Manuel Sánchez-Montañés, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 246, pp. 108011-108011
Open Access | Times Cited: 5
Prevention of infections including vaccination strategies in multiple myeloma
Heinz Ludwig, Shaji Kumar
American Journal of Hematology (2022) Vol. 98, Iss. S2
Open Access | Times Cited: 14
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response
Krischan Braitsch, Samuel Jeske, Jacob Stroh, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 871-871
Open Access | Times Cited: 1
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance
Matthew Ho, Saurabh Zanwar, Francis K. Buadi, et al.
Blood (2022) Vol. 140, Iss. 18, pp. 1997-2000
Open Access | Times Cited: 6
Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study
Omer S. Ashruf, Zara Orozco, David C. Kaelber
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 8, pp. 626-632
Open Access | Times Cited: 2
Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders
Nathanael R. Fillmore, Jennifer La, Julie Wu, et al.
Blood Advances (2023) Vol. 7, Iss. 21, pp. 6767-6770
Open Access | Times Cited: 2
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Ivo Demel, David Skopal, Eliška Šafránková, et al.
Annals of Hematology (2023) Vol. 103, Iss. 3, pp. 981-992
Open Access | Times Cited: 2
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
Saurabh Zanwar, Matthew Ho, Francis K. Buadi, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 11
Open Access
Page 1

Scroll to top